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Lysosomal acid lipase deficiency (LAL-D) is a rare autosomal recessive lysosomal storage disease
caused by deleterious mutations in the LIPA gene. The age at onset and rate of progression vary greatly
and this may relate to the nature of the underlying mutations. Patients presenting in infancy have the
most rapidly progressive disease, developing signs and symptoms in the first weeks of life and rarely
surviving beyond 6 months of age. Children and adults typically present with some combination of
dyslipidaemia, hepatomegaly, elevated transaminases, and microvesicular hepatosteatosis on biopsy.
Liver damage with progression to fibrosis, cirrhosis and liver failure occurs in a large proportion of
patients. Elevated low-density lipoprotein cholesterol levels and decreased high-density lipoprotein
cholesterol levels are common features, and cardiovascular disease may manifest as early as childhood.
Given that these clinical manifestations are shared with other cardiovascular, liver and metabolic
diseases, it is not surprising that LAL-D is under-recognized in clinical practice. This article provides
practical guidance to lipidologists, endocrinologists, cardiologists and hepatologists on how to
recognize individuals with this life-limiting disease. A diagnostic algorithm is proposed with a view to
achieving definitive diagnosis using a recently developed blood test for lysosomal acid lipase. Finally,
current management options are reviewed in light of the ongoing development of enzyme replace-
ment therapy with sebelipase alfa (Synageva BioPharma Corp., Lexington, MA, USA), a recombinant
human lysosomal acid lipase enzyme.
 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
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Lysosomal acid lipase deficiency (LAL-D) is a rare autosomal
recessive lysosomal storage disease characterized by progressive
accumulation of cholesteryl esters and triglycerides in the liver,
spleen and other organs [1]. Dyslipidaemia is a common finding in
patients with LAL-D that has been associated with accelerated
development of atherosclerosis, cardiovascular disease and pre-
mature mortality [1e3]. Progressive liver disease is another char-
acteristic feature of LAL-D, and patients typically present with
hepatomegaly, elevated transaminase levels and/or microvesicular
steatosis [1].
LAL-D is an under-recognized condition, with many affected
individuals receiving no diagnosis or incorrect diagnoses of het-
erozygous familial hypercholesterolaemia (HeFH), familial com-
bined hyperlipidaemia (FCH), non-alcoholic steatohepatitis
(NASH), non-alcoholic fatty liver disease (NAFLD) or cryptogenic
cirrhosis [4e6]. This review paper aims to provide recommenda-
tions to guide the timely diagnosis of LAL-D.2. Current understanding of lysosomal acid lipase deficiency
LAL-D is a heterogeneous disease that presents along a
clinical continuum, with signs and symptoms and rate of pro-
gression varying between affected individuals [1]. The most
rapidly progressive presentation occurs in infants, was first
described in 1956 and is referred to as Wolman disease [7]. A
few years later, Fredrickson reported the case of a 12-year-old
boy with marked hypercholesterolaemia, hepatomegaly and
cholesteryl ester accumulation on liver biopsy [8]. This later-
onset condition was named cholesteryl ester storage disease
(CESD). Since their initial characterization, it has been discov-
ered that Wolman disease and CESD share the same underlying
molecular pathology, resulting from mutations in the LIPA gene,which encodes lysosomal acid lipase (LAL), the enzyme
responsible for hydrolysing the cholesteryl esters and tri-
glycerides within low density lipoprotein (LDL) particles into
free cholesterol and free fatty acids [9e12]. The variable rates of
progression observed between patients with LAL-D are believed
to be related to the nature of the disease-causing mutations and
the resulting degree of residual enzyme activity [10,11]. How-
ever, there may be other contributing factors (e.g. environmental
influences) affecting disease progression.
Infants with LAL-D typically present in the first weeks of life and
die within 6e12 months due to multi-organ failure [10]. Clinical
signs may even arise during pregnancy, with reports of foetal as-
cites and polyhydramnios detected by prenatal ultrasonography
[13]. The hallmarks of the disease in infants consist of prominent
hepatosplenomegaly, diarrhoea and vomiting, resulting in malab-
sorption, growth failure and liver failure. These infants quickly
develop liver fibrosis and cirrhosis due to themassive accumulation
of cholesteryl esters and triglycerides in the liver [14]. Abnormal
lipid accumulation has also been described in the spleen, adrenal
glands, lymph nodes, intestinal mucosa, vascular endothelium and
skeletal muscle [14,15]. Approximately 50% of infants with LAL-D
have adrenal calcifications [1,16].
In children and adults, LAL-D has a more variable clinical
course than in infants. Mean age at symptom onset has been re-
ported to be 5 years in both male and female patients, although
clinical presentation has been documented as late as 44 years old
in men and 68 years old in women [1]. Lipid abnormalities may be
present at all ages, with a lipid profile that is indistinguishable
from that of more common genetic hypercholesterolaemias, such
as HeFH [17]. Liver dysfunction is common, with hepatomegaly
being an almost universal finding at diagnosis [1,18]. These
phenotypic features of LAL-D are non-specific and overlap with
other diseases, which may explain the common under-diagnosis
of this condition.
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Fig. 1. Schematic view of cellular cholesterol homoeostasis in (A) healthy individuals and (B) patients with LAL-D. ACAT, acyl-cholesterol acyltransferase; CE, cholesteryl esters; FA,
fatty acid; FC, free cholesterol; FFA, free fatty acid; HMG-CoA r, hydroxymethylglutaryl-coenzyme A reductase; LAL, lysosomal acid lipase; LAL-D, LAL deficiency; LDL-C, low-density
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LAL-D arises from mutations in the LIPA gene, which maps to
chromosome 10q23.2, has 10 exons and is approximately 45 kb in
length [15]. More than 40 loss-of-function mutations have been
identified to date (Supplemental Tables S1 and S2) [1,19]. LAL-D is
an autosomal recessive disease and affected individuals are typi-
cally either homozygous or compound heterozygous for LIPA mu-
tations, although some patients may have occult mutations. The
most severe alterations, such as nonsense mutations, frameshift
defects and point mutations resulting in stop codons, are generally
detected in affected infants (Supplemental Fig. S1A). Less severe
mutations are thought to occur in children and adults
(Supplemental Fig. S1B) [20].
The most commonly inherited defect is the exon 8 splice site
mutation, E8SJM (c.894G > A), which is found in more than half of
all children and adults with LAL-D [21,22]. The mutation in-
troduces an alternative acceptor splice site, resulting in the dele-
tion of exon 8 in mRNA. A small amount of the mRNA is spliced
correctly, which may result in the expression of some residual LAL
activity. Studies in the general population showed that the fre-
quency of the E8SJM allele is as follows: 0.0013 in Caucasians
(USA, 0.0017; Germany, 0.0025; EU, 0.0012), 0.0017 in US His-
panics, 0.0010 in US Ashkenazi Jews, 0.0005 in Asians and 0.0000
in AfricaneAmericans [23,24]. Based on the assumption that 50e
70% of children and adults with LAL-D have the E8SJM mutation
[21,22], it has been estimated that the overall disease prevalence
may be between 1 in 40,000 and 1 in 300,000 depending on
ethnicity and geographical location [1,15,21,23]. This estimate
conflicts with the small number of cases of LAL-D reported in the
literature, indicating that the disease may be substantially under-
diagnosed, especially in patients of European ancestry [1]. No
formal studies of the incidence of LAL-D in Europe have been
performed. A frequency of less than 1 in 700,000 has been re-
ported in Australia [25]. Jewish infants of Iraqi or Iranian origin
appear to be most at risk of LAL-D, with an estimated incidence of
1 in 4200 in the Los Angeles community [26].
The role of heterozygosity in LAL-D has not yet been studied in
depth. Evaluation of 13 individuals heterozygous for the E8SJM
mutation showed an altered lipid profile similar to that seen in
polygenic hypercholesterolaemia, conferring an increased cardio-
vascular risk [27]. To investigate this further, another study groupevaluated the frequency and impact of heterozygosity for the E8SJM
mutation on lipid levels in 13,194 individuals of European ancestry
[24]. In addition, to assess the impact of partial loss of LIPA function
on risk for myocardial infarction (MI) or coronary artery disease
(CAD), the frequency and impact of the E8SJM variant was evalu-
ated in 12,747 patients with MI/CAD and 14,725 controls free of MI
and CAD [24]. In both studies, no association between heterozy-
gosity and plasma lipid levels or risk for MI/CAD was observed [24].
It should be emphasized, however, that the number of heterozy-
gotes was rather small; thus additional studies are warranted to
substantiate whether heterozygotes develop some clinical features
of LAL-D and may be predisposed to sequelae such as atheroscle-
rosis and liver dysfunction.
2.2. Pathogenesis
LAL plays a key role in lipid metabolism through the hydrolysis
of cholesteryl esters and triglycerides in lysosomes (Fig. 1A). As
LDL-derived neutral lipids (cholesteryl esters and, to a lesser extent,
triglycerides) are degraded by LAL, the resulting free cholesterol
and fatty acids act as critical mediators in cellular cholesterol
homoeostasis [28]. These lipids or their oxidized derivatives
interact with transcription factors (sterol regulatory element-
binding proteins [SREBPs]) that directly modulate the expression
of genes involved in the synthesis and uptake of cholesterol and
lipogenesis [29]. Normally, an intracellular abundance of free
cholesterol leads to SREBP-2-mediated down-regulation of LDL
receptors (resulting in reduced entry of cholesterol into the cell),
feedback inhibition of hydroxymethylglutaryl-coenzyme A (HMG-
CoA) reductase (resulting in reduced cholesterol synthesis), and
stimulation of acyl-cholesterol acyltransferase (resulting in
enhanced cholesterol esterification). At the same time, intracellular
fatty acid enrichment leads to inhibition of phospholipid and tri-
glyceride production via SREBP-1c-mediated down-regulation of
fatty acid synthesis [30].
When LAL activity is absent or reduced, cholesteryl esters and
triglycerides are not degraded and accumulate within lysosomes
(Fig. 1B). The consequent scarcity of intracellular free cholesterol
causes the SREBP-mediated up-regulation of endogenous choles-
terol production by HMG-CoA reductase and of endocytosis via LDL
receptors, as well as increased synthesis of apolipoprotein B (ApoB)
and markedly increased production of very-low-density
Table 1
Summary illustrating range of clinical features, serum markers and liver biopsy
findings in children and adults with LAL-D.
Clinical signs
and symptoms
Hepatomegaly/hepatosplenomegaly
Diarrhoea
Abdominal and epigastric pain
Vomiting
Anaemia
Malabsorption
Cholestasis
Steatorrhoea
Poor growth
Gallbladder dysfunction
Coronary artery disease
Aneurysm
Stroke
Adrenal calcification (not required for diagnosis)
Oesophageal varices
Serum
markers
Elevated total cholesterol
Elevated low-density lipoprotein cholesterol
Decreased high-density lipoprotein cholesterol
Elevated serum transaminases
Liver biopsy
findings
Bright yelloweorange in colour
Enlarged lipid-laden hepatocytes and Kupffer cells
Microvesicular steatosis (may be mixed
with macrovesicular steatosis)
Fibrosis
Micronodular cirrhosis
LAL-D, lysosomal acid lipase deficiency.
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HMG-CoA reductase is the primary outcome of SREBP-2 sensing
intracellular cholesterol depletion, leading to an increase in free
cholesterol levels.
The impact of any increase in free cholesterol levels resulting
from the HMG-CoA reductase up-regulation observed in LAL-D is
not entirely understood, but it may cause feedback inhibition of LDL
receptor activity and reduced clearance of LDL-C from the circula-
tion. However, cholesterol trafficking in LAL-D does not seem to
follow this scheme. For example, the cellular uptake of LDL-C was
increased in LAL-deficient fibroblasts and uptake of ApoB was
normal in a patient with LAL-D [28,32]. In LAL-deficient hepato-
cytes, increases in cholesterol synthesis lead to great increases in
VLDLeC production and secretion, the natural way of exporting
cholesterol from the liver; this in turn leads to enhanced LDLeC
production and thus may be an important contributor to hyper-
cholesterolaemia in LAL-D [32].
In this context, the use of statins in patients with LAL-D raises
some concerns. Firstly it is unlikely that statins would reduce the
liver damage associated with accumulation of cholesterol esters in
the liver and there is evidence of persistence of elevation of serum
transaminases and continued progression of liver fibrosis to
cirrhosis in affected patients on statins [1,33]. Secondly, statins are
expected to reduce cholesterol synthesis, thus reducing the secre-
tion of ApoB containing lipoproteins and increasing the expression
of LDL receptors. This would translate into a reduction of plasma
LDL-C, but, in view of the higher receptor-mediated uptake of
plasma LDL-C, it would also be expected to accelerate lysosomal
accumulation of cholesteryl esters, with potentially deleterious
effects on liver function.
Interestingly, in sharp contrast with LAL-D, in another lysosomal
sterol storage disease, NiemannePick disease type C1 (NPC1),
circulating levels of total and LDL-C are reduced, not increased [34].
In patients with NPC1, free cholesterol accumulates in lysosomes
due to defects in NPC proteins involved in transporting the sterol to
the cytosolic compartment. However, some of the high levels of
intralysosomal free cholesterol may still be able to diffuse through
the organelle membrane to the exit site, resulting in a lesser
compensatory cholesterol synthesis (and presumably less VLDL-Ce
ApoB secretion) than in LAL-D, as shown in experimental studies
with lale/e, npc1/, and npc2/ mice [35].
Patients with LAL-D typically present with dyslipidaemia with
elevated serum total cholesterol, high LDL-C, low high-density li-
poprotein cholesterol (HDL-C) and may also have elevated tri-
glycerides [17]. The increase in total cholesterol and triglycerides is
due to accumulation in plasma of ApoB-containing lipoproteins
such as VLDL-C and LDL-C [36]. The reduction in HDL-C levels has
been linked, at least in vitro, to reduced formation of mature HDL
(a-HDL particles), secondary to decreased expression of the aden-
osine triphosphate-binding cassette transporter A1 (ABCA1).
Expression of the ABCA1 gene is induced by increased cell choles-
terol content, predominantly through an oxysterol-dependent
activation of the nuclear liver X-receptor (LXR), acting on the pro-
moter of the ABCA1 gene [37,38]. In LAL-D, the entrapment of
cholesteryl esters in lysosomes, and thus the reduction of the
intracellular free cholesterol pool, translates into: i) reduced oxy-
sterol formation and the consequent decreased activation of ABCA1
expression; and ii) a reduced amount of cholesterol in the subcel-
lular compartments and in the plasma membrane that is available
for the ABCA1-mediated transfer to the extracellular lipid-poor
apolipoprotein A1, the key event in the formation of a-HDL parti-
cles. These concepts are supported by the observation that the
addition of recombinant LAL to LAL-deficient cells rescues the
ABCA1-mediated cholesterol efflux to ApoA-I and HDL particle
formation [39].3. Signs and symptoms of lysosomal acid lipase deficiency
Presenting signs and symptoms of LAL-D may vary considerably
between patients. Many of the most common clinical manifesta-
tions, namely dyslipidaemia, hepatomegaly and liver cell damage
(as evidenced by increased serum transaminases with progression
to fibrosis and cirrhosis), are shared with other cardiovascular, liver
and metabolic diseases that are more prevalent than LAL-D
(Table 1).
Infants with LAL-D typically have a more acute clinical course
compared with children and adults. Gastrointestinal symptoms
(vomiting, diarrhoea with steatorrhoea and abdominal distension)
and growth failure are often the first manifestations to be
observed [15]. Abdominal distension is a striking feature, occur-
ring primarily due to massive hepatosplenomegaly. Characteristic
punctate calcifications of the adrenal glands may be observed on
radiological images in around 50% all infants and may also be seen
in children [1,15,16,40]. Anaemia may also be observed. Later
manifestations are related to multi-organ failure, particularly to
liver cirrhosis/failure, and include jaundice and cachexia [15]. Ef-
fects on the central nervous system are uncommon and those that
have been reported appear to be related to malnutrition and/or
specific nutritional deficiencies, or to complications of bone
marrow transplantation, rather than being related to LAL-D
directly [15,41].
The natural history of LAL-D in children and adults is less well
defined than in infants and detection of the disease is often inci-
dental [18]. For instance, a 36-year-old woman was admitted to
hospital because of hepatosplenomegaly and anaemia, and was
later diagnosed with LAL-D; however, a review of her medical re-
cords showed that at the age of 2 years she had developed jaundice,
hepatomegaly and slightly raised brownish skin spots, which
would have provided an early indication of the disease [42].
Approximately one-third of children experience severe gastroin-
testinal symptoms, including frequent diarrhoea, vomiting,
abdominal pain, malabsorption and steatorrhoea [1,18,43]. Chole-
stasis, poor growth, adrenal calcification, stroke and gallbladder
dysfunction have also been reported [1,40,44].
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Total plasma triglyceride and cholesterol levels are often normal
in infants with LAL-D, but elevated triglycerides and VLDL-C levels
have been reported in addition to lowplasmaHDL-C levels [45e48].
Children and adults with LAL-D often have type IIa or type IIb
hyperlipidaemia [17,18,49e55], exemplified by elevated total
cholesterol, elevated LDL-C, elevated ApoB and decreased HDL-C
levels [1,56]. Dyslipidaemia has been associated with atheroscle-
rosis and premature cardiovascular disease [1e3,5,42,57], as
demonstrated by the detection of an aortic plaque in a child with
LAL-D who died at the age of 9 years [40]. Intriguingly, three large
case-controlled genome-wide association studies showed that
increased expression of LIPA in blood monocytes is a risk factor for
coronary artery disease. [58e60] LIPA expression is markedly
upregulated during differentiation tomacrophages and it is unclear
what relevance the small observed differences in monocytes have
to final expression levels in tissue macrophages. In practice, how-
ever, morbidities related to liver disease are recognized more
frequently than vascular events in patients with LAL-D.3.2. Effects on the liver and spleen
Infants with LAL-D often present with failure to thrive, hepa-
tomegaly, with rapid progression to hepatocellular failure along
with liver fibrosis and cirrhosis [14,15]. The spleen may also be
enlarged and can reach over 20 times normal size by 2e3months of
age [61]. Hepatomegaly and splenomegaly are observed in
approximately 99% and 74%, respectively, of children and adults
with LAL-D [1,62]. Elevated levels of serum alanine aminotrans-
ferase (ALT) and/or aspartate aminotransferase (AST) are early in-
dicators of liver damage, although values may only be slightly
raised and can vary widely between patients. Clinical manifesta-
tions range from severe liver disease (i.e. oesophageal varices, liver
failure) that may be present in early childhood, to asymptomatic
low grade liver injury (i.e. elevated transaminases), with silent
progression to cirrhosis in late adulthood.
On biopsy, the liver appears bright yelloweorange in colour, and
histological analysis shows varying degrees of portal and peril-
obular fibrosis and intense microvesicular steatosis due to accu-
mulation of cholesteryl esters and triglycerides in the lysosomes of
hepatocytes [4]. A characteristic feature is the presence of markedly
hypertrophic Kupffer cells and portal macrophages, with a foamy,Fig. 2. . Hepatocytes show microvesicular steatosis (green arrows). The foamy Kupffer
cell (red block arrow) in the perivenular zone is PAS positive (PAS after diastase
digestion, original magnification  630). PAS, periodic acideSchiff. (For interpretation
of the references to color in this figure legend, the reader is referred to the web version
of this article.)tan-coloured cytoplasm that stains strongly with periodic acide
Schiff (PAS). The membranes of such vacuoles are well stained by
PAS diastase (Fig. 2). In unfixed biopsy samples, the presence of
birefringent-stored liquid crystals of cholesteryl esters is an addi-
tional diagnostic clue in LAL-D. Immunohistochemical detection of
luminal cathepsin D and lysosomal markers (lysosomal-associated
membrane protein [LAMP1, LAMP2] and lysosomal integral mem-
brane protein 2) around the lipid droplets is also a very useful
indication of LAL-D [4]. Cholesteryl esters and triglyceride droplets
of varying size can be noted in both parenchymal and Kupffer cells,
mostly surrounded by a single membrane. Some of the lipid vac-
uoles may contain star-like crystalline imprints of cholesteryl esters
that dissolved during sample preparation, giving the stored mate-
rial a moth-eaten appearance [14].
Progressive lipid deposition leads to fibrosis (present in two-
thirds of individuals affected during childhood or adulthood) and,
eventually, micronodular cirrhosis [4,18]. Complications associated
with cirrhosis include portal hypertension, ascites, oesophageal
varices, gastrointestinal bleeding, cachexia and coma, which often
progress to liver failure and death [1].
4. Differential diagnoses
Owing to its similarity with other cardiovascular, liver and
metabolic diseases, the differential diagnosis of LAL-D can be chal-
lenging. Without appropriate investigation, these similarities can
lead to misdiagnosis and a delay in appropriate management [1,17].
Serum lipid levels in LAL-D may vary, but most children and
adults present with elevated total cholesterol and LDL-C and
reduced HDL-C levels [1]. Common misdiagnoses include HeFH,
familial defective ApoB, FCH and polygenic hypercholesterolaemia
[17,18,51e55]. Nevertheless, it is possible to distinguish LAL-D from
these conditions based on a few simple principles. First, a detailed
family history/pedigree analysis can delineate autosomal dominant
disorders (e.g. HeFH, FCH and polygenic hypercholesterolaemia)
from autosomal recessive disorders (e.g. LAL-D and sitoster-
olaemia). Secondly, total cholesterol and LDL-C levels in LAL-D may
not be as high as in HeFH. Additionally, HDL-C levels are usually
lower in LAL-D than in HeFH, but may overlap with levels seen in
patients with HeFH [63]. The potential for similar lipid profiles
suggest that physicians should beware of the possibility of LAL-D
when considering HeFH as a diagnosis.
Although liver abnormalities observed in LAL-D are well char-
acterized, the rate of progression and therefore presentation of
symptoms of liver disease are not always consistent [2]. For
example, hepatomegaly is observed in most, but not all [24,64],
patients, and some may have only slightly elevated or, rarely,
normal levels of serum transaminases. In those with hepatomegaly
and persistently elevated serum transaminases, incorrect diagnoses
may include NAFLD, NASH or cryptogenic liver disease, or no
diagnosis at all [1]. A full viral/immunological profile should be
carried out to exclude more common disorders such as viral hep-
atitis and autoimmune liver disease [50]. Unlike individuals with
metabolic syndrome, which is also associated with dyslipidaemia,
fatty liver and elevated liver transaminases, patients with LAL-D
may not be obese. Therefore, non-obese patients with these liver
manifestations may help in differentiating LAL-D from other con-
ditions like metabolic syndrome.
5. Screening for lysosomal acid lipase deficiency
To aid the timely diagnosis of LAL-D, a diagnostic algorithm is
proposed based on the clinical experience of the authors (Fig. 3). In
light of the heterogeneous phenotype of LAL-D, it is not necessary
for a patient to fulfil all of the criteria listed before LAL-D is
Fig. 3. Recommended screening criteria for LAL-D in patients at baseline assessment or not receiving lipid-lowering therapies. ALT, alanine aminotransferase; BMI, body mass
index; DBS, dried blood spot; FCH, familial combined hyperlipidaemia; HeFH, heterozygous familial hypercholesterolaemia; HDL-C, high-density lipoprotein cholesterol; LAL,
lysosomal acid lipase; LAL-D, lysosomal acid lipase deficiency; LDL-C, low-density lipoprotein cholesterol; LAL gene. aOr below the 95th percentile for age and sex in children and
adults [65]. It should be noted that LDL-C might be lower in some patients with LAL-D, especially in those receiving statins. bUpper limit of normal for age and sex in healthy
individuals, with no clear explanation (e.g. viral hepatitis, excessive alcohol consumption). It should be noted that, owing to periodic fluctuations in ALT levels, this sign may not
always be detected. cOr above the 95th percentile for age and sex in children and adults [65]. It should be noted, however, that BMI may be above 30 in some patients with LAL-D,
depending on diet. dPlease note that liver biopsy is not recommended as a diagnostic method for LAL-D. eWhen measured by DBS testing, mean LAL activity is approximately 1.00
nmol/punch/hour in healthy individuals [66]. LAL activity less than or equal to 0.03 nmol/punch/hour (3% mean normal) is considered consistent with LAL-D. Marginal LAL activity
is defined as a measurement between 0.03 nmol/punch/hour and 0.15 nmol/punch/hour (i.e. 3e15% mean normal). Patients with LAL activity in this range should be referred for
molecular sequencing of the LIPA gene. Readers should note that reference ranges will vary between laboratories.
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been designed to be sufficiently broad so that a patient meeting any
three or more of the listed criteria should be tested for LAL-D.
The absence of family history of hyperlipidaemia may indicate
autosomal recessive inheritance, as would the absence of a genetic
mutation indicative of HeFH. Although liver biopsy is not recom-
mended as a diagnostic procedure, the presence of microvesicular
steatosis on biopsy may be suggestive of LAL-D.
It should be noted that the reference ranges for some parame-
ters are age-dependent, and this must be taken into account. For
instance, reference ranges for LDL-C levels will typically be lower in
children and adolescents than in adults [65]; however, experience
is limited, especially in very young children [18]. To avoid a missed
diagnosis, clinical suspicion should be raised for any child with alipid profile consistent with HeFH or FCH (i.e. above the 95th
percentile for age and sex) [65].
6. Investigations to diagnose LAL-D
A diagnosis of LAL-D can be obtained by demonstration of
deficient LAL activity or mutations in the LIPA gene [1]. Biopsy
findings and radiological findings are not considered diagnostic,
but help raise the suspicion of LAL-D.
6.1. Measurement of LAL activity
LAL-D can be confirmed biochemically by measuring enzyme
activity in cultured fibroblasts, peripheral leukocytes or liver tissue.
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may not be specific for LAL, so it is theoretically possible for a false-
negative result to be generated. A newmethod for determining LAL
activity in dried blood has been developed and has been found to
detect affected patients [66]. LAL activity is measured using the
fluorimetric substrate 4-methylumbelliferyl palmitate. Other li-
pases inwhole bloodmay interferewith themeasurement of LAL in
dried blood spots (DBS) [67], so a LAL inhibitor is used. Lalistat 2
(Chemical Tools, South Bend, IN, USA) is a highly specific inhibitor
of LAL that has been developed previously as a potential thera-
peutic target for NPC1 [68]. LAL activity is determined by
comparing total lipase activity to lipase activity in the presence of
Lalistat 2; the difference between the two results can be attributed
to LAL enzyme. The method demonstrates excellent differentiation
between healthy and affected individuals, with carriers showing
intermediate LAL activity. A feature of the assay is that significantly
reduced activity (<3% of normal) falls below the limit of detection,
meaning that it is not possible to distinguish between LAL-D pre-
senting in infants versus presentation in older patients.
The blood test for LAL has been a powerful tool in allowing
screening programmes and large population-based surveys for
LAL-D to be undertaken and it may be adapted for newborn
screening. The DBS technique has many advantages, including a
small sample volume (50 mL whole blood) and transport to
specialist laboratories at ambient temperature. Sample stability
shows a 15% fall in LAL activity after 7 days at room temperature.
With prompt transport of samples, however, LAL activity in DBS is
adequate for diagnostic purposes. Long-term stability at 20 C is
good, with 87% activity remaining at 100 days [66]. Supplemental
Table S3 lists laboratories capable of performing the analysis of
DBS samples.
6.2. Genetic testing
Complete sequencing of the coding regions of LIPA enables
characterization of the genetic status of individuals with suspected
LAL-D [15]. Although themost commonmutation, E8SJM, is present
in 50e70% of mutant alleles in children and adults with LAL-D, the
low frequency of the E8SJM mutation in some populations (e.g.
those of AfricaneAmerican and Asian descent) means that
screening for the common mutation via the polymerase chain re-
action assay may not be adequate in these populations [23].
Although most affected patients are homozygous or compound
heterozygous for LIPA mutations, some patients may have intronic
mutations that go undetected in routine genetic screening. In light
of this, the utilization of sequencing to diagnose LAL-D might be
replaced with the easily accessible, accurate and low-cost DBS
assay.
6.3. Liver biopsy
Liver biopsy is generally regarded as the most reliable method
for evaluating liver abnormalities. However, the risk of biopsy-
related morbidity and mortality and the costs associated with this
procedure limit its widespread application [69]. Furthermore,
sampling error canmake diagnosis by this method difficult. Current
guidelines suggest that liver biopsy should only be used to obtain a
diagnosis if a conclusion cannot be reached by other non-invasive
means, such as a blood test [69,70].
The presence of microvesicular steatosis on liver biopsy is not
unique to LAL-D, so other histological signs are needed to confirm a
diagnosis. Hypertrophic Kupffer cells and portal macrophages with
a foamy, tan-coloured cytoplasm are a characteristic feature of LAL-
D in children and adults. The presence of luminal and membrane
lysosomal markers around lipid vacuoles is indicative of LAL-D infixed paraffin-embedded material, as are pathognomonic choles-
teryl ester crystals in unfixed samples [4].
6.4. Radiological techniques
Hepatic magnetic resonance spectroscopy using a 3T magnetic
resonance imaging (MRI) scanner has recently been described as a
useful non-invasive method to identify and to quantify the hepatic
lipid signature associated with LAL-D [71]. This approach may
provide a more favourable alternative to repeated biopsy sampling
for diagnosis and disease monitoring.
7. Management and therapies in development
No disease-specific treatments are currently available for pa-
tients with LAL-D. Existing approaches focus on supportive thera-
pies to reduce the burden of disease complications. Clinical trials
are ongoing to investigate the safety and efficacy of sebelipase alfa
(Synageva BioPharma Corp., Lexington, MA, USA), a recombinant
human lysosomal acid lipase that addresses the underlying defect
in LAL-D patients.
7.1. Lipid-lowering therapies
Statins (HMG-CoA-reductase inhibitors) are well-tolerated LDL-
C-lowering agents known to reduce the risk of cardiovascular dis-
ease [72]. In children and adults with LAL-D, statins as mono-
therapy or in combination with other lipid-lowering drugs were
found to reduce LDL-C in many cases reported in the literature, but
elevations were still reported in some patients [5,17,32,36,64,73e
77]. A recent observational study also noted that dyslipidaemia
persists despite treatment with lipid-lowering therapies in many
patients with LAL-D [33]. In some patients with LAL-D, statin
therapy was associated with a significant decrease in endogenous
cholesterol synthesis in fibroblasts [32,36]. In another study, the
authors concluded that a decrease in circulating LDL-C was due to
reduced hepatic production of ApoB-containing lipoproteins [36].
Although statin therapy can lower plasma LDL-C levels and reduce
cardiovascular risk in many patient populations, there is evidence
that hepatic damage progresses in patients with LAL-D in spite of
treatment [1,36]. A reduction in liver size has been reported in
some patients with LAL-D treated with statins [36,73]; however,
the liver fibrosis continued to progress in all individuals followed
long term [1,15,77]. Similarly, a recent review revealed that in 12
patients treated with statins, liver histology did not improve [1]. In
subsequent biopsies, all 12 patients had progressive liver disease
that was more advanced than before, demonstrating the progres-
sive nature of liver disease in LAL-D. In fact, six patients treated
with statins required transplantation or died from liver failure [1].
Further research in this field is needed.
Ezetimibe (a cholesterol absorption inhibitor) has been re-
ported to normalize liver transaminases and reduce total choles-
terol and LDL-C levels (30% and 25%, respectively) in a 15-year-old
boy with LAL-D after 6 months of treatment [78]. Serum levels of
cytokines and oxidative stress parameters, which were elevated at
baseline, were also found to normalize after 1 year of ezetimibe
therapy. [78]
7.2. Vitamin E
In an in vitro study, tocopherol, a compound with vitamin E
activity, was found to promote lysosomal exocytosis and thus
reduce lipid accumulation in fibroblasts harvested from patients
with NPC1 and infants with LAL-D [79]. Unfortunately, trans-
lating these cell-based results into in vivo studies in animals and
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macokinetics of tocopherol. To achieve a therapeutic effect
in vitro, a supraphysiological concentration of tocopherol was
deployed; even with dietary supplementation, it is unlikely that
high concentrations will be achievable in vivo owing to rapid
oxidation of vitamin E derivatives by the cytochrome P450
enzyme CYP4F2.7.3. Haematopoietic stem cell and liver transplantation
Haematopoietic stem cell transplantation has been performed
in a few infants with LAL-D [13,80]. However, this approach has had
limited success in addressing the multi-system nature of the dis-
ease and has been associatedwith high toxicity and challenges with
sustained engraftment in target tissues [80e82]. Follow-up data
show survival in some patients with LAL-D up to 5 years after liver
transplantation, but for many there is limited information on long-
term outcomes and other co-morbidities [1,83,84].7.4. Enzyme replacement therapy
Enzyme replacement therapy (ERT) has been used successfully
in other lysosomal storage diseases and is a potential future therapy
for patients with LAL-D [85]. The goal of ERT for LAL-D is to rein-
state near-physiological enzyme levels to prevent the accumulation
of cholesteryl esters and triglycerides, and ultimately restore
normal organ function.
Sebelipase alfa, a recombinant human LAL enzyme, is
currently in phase 3 clinical trials. Data from the first human
studies with sebelipase alfa, an open-label phase 2 trial (LAL-
CL01) in 9 adults with LAL-D and an ongoing extension study
(LAL-CL04) in 7 of these patients, have been reported [86,87]. In
the first study, patients received four once-weekly infusions,
which were well tolerated and resulted in a rapid decrease of
liver transaminases and increases of total cholesterol, LDL-C and
triglycerides, suggesting mobilization of accumulated lipid in
tissues [86]. After the LAL-CL01 trial was completed and patients
stopped sebelipase alfa, both liver enzymes and lipid levels
returned to baseline values. Patients who enrolled in the exten-
sion study again received four once-weekly infusions of sebeli-
pase alfa before transitioning to long-term every-other week
infusions (1 or 3 mg/kg). After 78 weeks of treatment with
sebelipase alfa in seven patients, both ALT and AST continued to
be reduced compared with baseline, falling into the normal
range. In addition, sebelipase alfa treatment for these patients,
many of whom were on stable doses of lipid-lowering agents, led
to mean 52% and 40% reductions in LDL-C and triglyceride levels,
respectively, and a mean 37% improvement in HDL-C [87]. Re-
ductions from baseline were also observed for liver fat fraction
(mean, 55%) and liver volume (mean, 12%) at week 52, the latest
time point for these assessments [87]. More than 250 infusions
have been administered thus far in the trial and no serious safety
concerns have emerged with long-term dosing. There were no
drug-related serious adverse events. The majority of adverse
events were mild and unrelated to sebelipase alfa. Infusion-
related reactions were uncommon and most were mild gastro-
intestinal events (diarrhoea, abdominal cramping).
The efficacy and safety of sebelipase alfa for LAL-D are being
assessed in a randomized, double-blind, placebo-controlled, phase
3 trial (“ARISE” trial; ClinicalTrials.gov identifier: NCT01757184). In
addition, an open-label, multicentre, phase 2/3 study in infants
with LAL-D presenting with growth failure is also ongoing
(ClinicalTrials.gov identifier: NCT01371825). Data from these
studies are expected to be released in 2014.8. Disease monitoring
Given the progressive nature of LAL-D, patients should undergo
annual evaluations to monitor disease progression. Recommended
laboratory procedures include liver function tests, full blood counts,
lipid profile and measurement of plasma levels of chitotriosidase (a
chitinase that is markedly increased in many lysosomal storage
diseases) [1]. Dyslipidaemia and any other cardiovascular risk fac-
tors should be managed according to current guidelines for high-
risk patients [88]. Imaging studies should be performed periodi-
cally to evaluate liver and spleen volumes. Similarly, magnetic
resonance spectroscopy or multi-echo gradient-echo MRI can be
used to monitor hepatic fat content [71]. Imaging studies to
monitor liver fibrosis, portal hypertension and risk of variceal
bleeding should be considered according to clinical judgement.
9. Prognosis
Disease progression and the impact of clinical manifestations on
daily life vary from patient to patient. Some children with LAL-D
suffer early liver failure and require transplantation [1], and car-
diovascular complications of LAL-D may include coronary artery
disease, aneurysm and stroke [5,42,57,89,90]. Clearly, these severe
signs and symptoms will have a negative effect on quality of life;
however, no validated patient-reported outcome or quality of life
measures have been developed for LAL-D. Individuals with less
obvious signs and symptoms may remain undetected or mis-
diagnosed until a premature cardiovascular event or sudden death
from liver failure.
10. Discussion
Dyslipidaemia is a characteristic feature of LAL-D in children and
adults, and many patients are likely to be referred to lipid clinics
before diagnosis. Given the similarities between the lipid profile
observed in patients with LAL-D and that of common genetic
hyperlipidaemias such as HeFH and FCH, it is important that lip-
idologists remain vigilant to avoid misdiagnosis. Similarly, the he-
patic manifestations of the disease may be confused with disorders
such as NAFLD, NASH or cryptogenic liver disease.
Early recognition and diagnosis of individuals with LAL-D is
essential if appropriate care is to be provided. After reviewing the
relevant data, we have proposed a diagnostic algorithm that can be
used in most lipid clinics. The recent development of a blood test
for LAL-D provides physicians with a method for rapid diagnosis of
LAL-D.
Current management of LAL-D focuses on lipid control and
amelioration of liver complications. The limited success of statins in
treating all aspects of LAL-D means that alternative, disease-
specific treatments are needed. The ongoing development of
sebelipase alfa offers a disease-specific therapeutic approach that
may change the natural course of the disease. However, there is a
need for enhanced awareness of LAL-D so that early diagnosis can
help limit disease-associated morbidity and mortality.
Lipidologists, endocrinologists, cardiologists and hepatologists
are likely to be confronted with LAL-D in clinical practice and
should be aware of the hallmarks of the disease. We all have a re-
sponsibility to raise awareness of LAL-D as a potential diagnosis in
patients presenting with signs and symptoms usually associated
with more common cardiovascular, liver and metabolic diseases.
Declaration of conflicts of interest
DN has no conflicts of interest to declare.
Z. Reiner et al. / Atherosclerosis 235 (2014) 21e30 29ER has received a research grant from Synageva BioPharma
Corp.
KH has received a research grant from Synageva BioPharma
Corp. and participates in a multicentre research project sponsored
by Synageva BioPharma Corp. KH has received lecture fees from
Amgen, Genzyme, Pfizer, Roche and Sanofi.
HS has received a research grant from Synageva BioPharma
Corp.
JH has received honoraria from Synageva BioPharma Corp. for
organizing training courses for LAL testing in DBS.
MC has no conflicts of interest to declare.
OG has received travel expenses for presenting at scientific
meetings sponsored by Synageva BioPharma Corp.
SB has no conflicts of interest to declare.
SC has no conflicts of interest to declare.
SJ has received lecturer’s honoraria and consultancy fees from
Synageva BioPharma Corp., and is a clinical trial investigator for
sebelipase alfa.
TE was employed at Synageva BioPharma Corp.
ZR has received lecturer’s honoraria from Abbott and AstraZe-
neca and has served on advisory boards for Sanofi.Acknowledgements
Scientific editorial assistance was provided by Dr Jonathan
Morton (Oxford PharmaGenesis Ltd, UK) and was funded by
Synageva BioPharma Corp. (Lexington, MA, USA). In addition, we
would like to thank Dr Radhika Tripuraneni (Synageva BioPharma
Corp.) for sharing scientific and clinical insights from ongoing work
on LAL-D and for her review and assistance in preparing this re-
view. CIBERobn is an initiative of Instituto de Salud Carlos III, Spain.
All the authors had full editorial control of the content and
approved the final version.Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.atherosclerosis.2014.04.003.References
[1] Bernstein DL, Hulkova H, Bialer MG, Desnick RJ. Cholesteryl ester storage
disease: review of the findings in 135 reported patients with an under-
diagnosed disease. J Hepatol 2013;58:1230e43.
[2] Elleder M, Chlumska A, Hyanek J, Poupetova H, Ledvinova J, Maas S, et al.
Subclinical course of cholesteryl ester storage disease in an adult with hy-
percholesterolemia, accelerated atherosclerosis, and liver cancer. J Hepatol
2000;32:528e34.
[3] Elleder M, Chlumska A, Ledvinova J, Poupetova H. Testis  a novel storage site
in human cholesteryl ester storage disease. Autopsy report of an adult case
with a long-standing subclinical course complicated by accelerated athero-
sclerosis and liver carcinoma. Virchows Arch 2000;436:82e7.
[4] Hulkova H, Elleder M. Distinctive histopathological features that support a
diagnosis of cholesterol ester storage disease in liver biopsy specimens. His-
topathology 2012;60:1107e13.
[5] Gasche C, Aslanidis C, Kain R, Exner M, Helbich T, Dejaco C, et al. A novel
variant of lysosomal acid lipase in cholesteryl ester storage disease associated
with mild phenotype and improvement on lovastatin. J Hepatol 1997;27:
744e50.
[6] Chatrath H, Keilin S, Attar BM. Cholesterol ester storage disease (CESD)
diagnosed in an asymptomatic adult. Dig Dis Sci 2009;54:168e73.
[7] Abramov A, Schorr S, Wolman M. Generalized xanthomatosis with calcified
adrenals. AMA J Dis Child 1956;91:282e6.
[8] Fredrickson DS. Newly recognized disorders of cholesterol metabolism. Ann
Intern Med 1963;58:718.
[9] Burke JA, Schubert WK. Deficient activity of hepatic acid lipase in cholesterol
ester storage disease. Science 1972;176:309e10.
[10] Aslanidis C, Ries S, Fehringer P, Buchler C, Klima H, Schmitz G. Genetic and
biochemical evidence that CESD and Wolman disease are distinguished by
residual lysosomal acid lipase activity. Genomics 1996;33:85e93.[11] Pagani F, Pariyarath R, Garcia R, Stuani C, Burlina AB, Ruotolo G, et al. New
lysosomal acid lipase gene mutants explain the phenotype of Wolman disease
and cholesteryl ester storage disease. J Lipid Res 1998;39:1382e8.
[12] Patrick AD, Lake BD. Deficiency of an acid lipase in Wolman’s disease. Nature
1969;222:1067e8.
[13] Stein J, Garty BZ, Dror Y, Fenig E, Zeigler M, Yaniv I. Successful treatment of
Wolman disease by unrelated umbilical cord blood transplantation. Eur J
Pediatr 2007;166:663e6.
[14] Boldrini R, Devito R, Biselli R, Filocamo M, Bosman C. Wolman disease and
cholesteryl ester storage disease diagnosed by histological and ultrastructural
examination of intestinal and liver biopsy. Pathol Res Pract 2004;200:231e40.
[15] Grabowski GA, Charnas L, Du H. Lysosomal acid lipase deficiencies: the
Wolman disease/cholesteryl ester storage disease spectrum. In: Valle D,
Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, editors.
Scriver’s online metabolic and molecular bases of inherited disease. McGraw
Hill; [accessed 28.10.13], http://www.ommbid.com/OMMBID/the_online_
metabolic_and_molecular_bases_of_inherited_disease/b/abstract/part16/
ch142.
[16] Jones SA, Bernstein DL, Bialer MG, Dhawan A, Hendriksz JC, Whitley CB, et al.
Severe and rapid disease course in the natural history of infants with lyso-
somal acid lipase deficiency. Mol Genet Metab 2014;111:S57e8.
[17] Fouchier SW, Defesche JC. Lysosomal acid lipase A and the hyper-
cholesterolaemic phenotype. Curr Opin Lipidol 2013;24:332e8.
[18] Zhang B, Porto AF. Cholesteryl ester storage disease: protean presentations of
lysosomal acid lipase deficiency. J Pediatr Gastroenterol Nutr 2013;56:682e5.
[19] Reynolds T. Cholesteryl ester storage disease: a rare and possibly treatable cause
of premature vascular disease and cirrhosis. J Clin Pathol 2013;66:918e23.
[20] Saito S, Ohno K, Suzuki T, Sakuraba H. Structural bases of Wolman disease and
cholesteryl ester storage disease. Mol Genet Metab 2012;105:244e8.
[21] Muntoni S, Wiebusch H, Jansen-Rust M, Rust S, Seedorf U, Schulte H, et al.
Prevalence of cholesteryl ester storage disease. Arterioscler Thromb Vasc Biol
2007;27:1866e8.
[22] Lohse P, Maas S, Elleder M, Kirk JM, Besley GT, Seidel D. Compound hetero-
zygosity for a Wolman mutation is frequent among patients with cholesteryl
ester storage disease. J Lipid Res 2000;41:23e31.
[23] Scott SA, Liu B, Nazarenko I, Martis S, Kozlitina J, Yang Y, et al. Frequency of
the cholesteryl ester storage disease common LIPA E8SJM mutation
(c.894G>A) in various racial and ethnic groups. Hepatology 2013;58:958e65.
[24] Stitziel NO, Fouchier SW, Sjouke B, Peloso GM, Moscoso AM, Auer PL, et al.
Exome sequencing and directed clinical phenotyping diagnose cholesterol
ester storage disease presenting as autosomal recessive hypercholesterole-
mia. Arterioscler Thromb Vasc Biol 2013;33:2909e14.
[25] Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage
disorders. J Am Med Assoc 1999;281:249e54.
[26] Valles-Ayoub Y, Esfandiarifard S, No D, Sinai P, Khokher Z, Kohan M, et al.
Wolman disease (LIPA p.G87V) genotype frequency in people of Iranian-
Jewish ancestry. Genet Test Mol Biomarkers 2011;15:395e8.
[27] Muntoni S, Wiebusch H, Jansen-Rust M, Rust S, Schulte H, Berger K, et al.
Heterozygosity for lysosomal acid lipase E8SJM mutation and serum lipid
concentrations. Nutr Metab Cardiovasc Dis 2013;23:732e6.
[28] Goldstein JL, Dana SE, Faust JR, Beaudet AL, Brown MS. Role of lysosomal acid
lipase in the metabolism of plasma low density lipoprotein. Observations in
cultured fibroblasts from a patient with cholesteryl ester storage disease.
J Biol Chem 1975;250:8487e95.
[29] Jeon TI, Osborne TF. SREBPs: metabolic integrators in physiology and meta-
bolism. Trends Endocrinol Metab 2012;23:65e72.
[30] Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete pro-
gram of cholesterol and fatty acid synthesis in the liver. J Clin Invest
2002;109:1125e31.
[31] Cummings MH, Watts GF. Increased hepatic secretion of very-low-density
lipoprotein apolipoprotein B-100 in cholesteryl ester storage disease. Clin
Chem 1995;41:111e4.
[32] Ginsberg HN, Le NA, Short MP, Ramakrishnan R, Desnick RJ. Suppression of
apolipoprotein B production during treatment of cholesteryl ester storage
disease with lovastatin. Implications for regulation of apolipoprotein B syn-
thesis. J Clin Invest 1987;80:1692e7.
[33] Quinn AG, Burton B, Deegan P, Di Rocco M, Enns GM, Guardamagna O, et al.
Sustained elevations in LDL cholesterol and serum transaminases from early
childhood are common in lysosomal acid lipase deficiency. Mol Genet Metab
2014;111:S89.
[34] Garver WS, Jelinek D, Meaney FJ, Flynn J, Pettit KM, Shepherd G, et al. The
National NiemannPick type C1 disease database: correlation of lipid profiles,
mutations, and biochemical phenotypes. J Lipid Res 2010;51:406e15.
[35] Ramirez CM, Liu B, Aqul A, Taylor AM, Repa JJ, Turley SD, et al. Quantitative
role of LAL, NPC2, and NPC1 in lysosomal cholesterol processing defined by
genetic and pharmacological manipulations. J Lipid Res 2011;52:688e98.
[36] Levy R, Ostlund Jr RE, Schonfeld G, Wong P, Semenkovich CF. Cholesteryl ester
storage disease: complex molecular effects of chronic lovastatin therapy.
J Lipid Res 1992;33:1005e15.
[37] Oram JF, Heinecke JW. ATP-binding cassette transporter A1: a cell cholesterol
exporter that protects against cardiovascular disease. Physiol Rev 2005;85:
1343e72.
[38] Boadu E, Bilbey NJ, Francis GA. Cellular cholesterol substrate pools for
adenosine-triphosphate cassette transporter A1-dependent high-density li-
poprotein formation. Curr Opin Lipidol 2008;19:270e6.
Z. Reiner et al. / Atherosclerosis 235 (2014) 21e3030[39] Bowden KL, Bilbey NJ, Bilawchuk LM, Boadu E, Sidhu R, Ory DS, et al. Lyso-
somal acid lipase deficiency impairs regulation of ABCA1 gene and formation
of high density lipoproteins in cholesteryl ester storage disease. J Biol Chem
2011;286:30624e35.
[40] Beaudet AL, Ferry GD, Nichols Jr BL, Rosenberg HS. Cholesterol ester storage
disease: clinical, biochemical, and pathological studies. J Pediatr 1977;90:
910e4.
[41] Eto Y, Kitagawa T. Wolman’s disease with hypolipoproteinemia and acan-
thocytosis: clinical and biochemical observations. J Pediatr 1970;77:862e7.
[42] vom Dahl S, Harzer K, Rolfs A, Albrecht B, Niederau C, Vogt C, et al. Hep-
atosplenomegalic lipidosis: what unless Gaucher? Adult cholesteryl ester
storage disease (CESD) with anemia, mesenteric lipodystrophy, increased
plasma chitotriosidase activity and a homozygous lysosomal acid lipase -1
exon 8 splice junction mutation. J Hepatol 1999;31:741e6.
[43] Drebber U, Andersen M, Kasper HU, Lohse P, Stolte M, Dienes HP. Severe
chronic diarrhea and weight loss in cholesteryl ester storage disease: a case
report. World J Gastroenterol 2005;11:2364e6.
[44] Haller W, Sharif K, Millar AJ, Brown RM, McKiernan PJ. Gallbladder dysfunc-
tion in cholesterol ester storage disease. J Pediatr Gastroenterol Nutr 2010;50:
555e8.
[45] Schaub J, Janka GE, Christomanou H, Sandhoff K, Permanetter W, Hubner G,
et al. Wolman’s disease: clinical, biochemical and ultrastructural studies in an
unusual case without striking adrenal calcification. Eur J Pediatr 1980;135:
45e53.
[46] Wallis K, Gross M, Kohn R, Zaidman J. A case of Wolman’s disease. Helv
Paediatr Acta 1971;26:98e111.
[47] Kyriakides EC, Filippone N, Paul B, Grattan W, Balint JA. Lipid studies in
Wolman’s disease. Pediatrics 1970;46:431e6.
[48] Marshall WC, Ockenden BG, Fosbrooke AS, Cumings JN. Wolman’s disease. A
rare lipidosis with adrenal calcification. Arch Dis Child 1969;44:331e41.
[49] Kostner GM, Hadorn B, Roscher A, Zechner R. Plasma lipids and lipoproteins
of a patient with cholesteryl ester storage disease. J Inherit Metab Dis 1985;8:
9e12.
[50] Decarlis S, Agostoni C, Ferrante F, Scarlino S, Riva E, Giovannini M. Combined
hyperlipidaemia as a presenting sign of cholesteryl ester storage disease.
J Inherit Metab Dis 2009;32(Suppl. 1):S11e3.
[51] Gaddi A, Cicero AF, Odoo FO, Poli AA, Paoletti R. Practical guidelines for fa-
milial combined hyperlipidemia diagnosis: an up-date. Vasc Health Risk
Manag 2007;3:877e86.
[52] Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al.
ESC/EAS guidelines for the management of dyslipidaemias: the task force for
the management of dyslipidaemias of the European Society of Cardiology
(ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:
1769e818.
[53] Cortner JA, Coates PM, Gallagher PR. Prevalence and expression of familial
combined hyperlipidemia in childhood. J Pediatr 1990;116:514e9.
[54] Guardamagna O, Restagno G, Rolfo E, Pederiva C, Martini S, Abello F, et al. The
type of LDLR gene mutation predicts cardiovascular risk in children with fa-
milial hypercholesterolemia. J Pediatr 2009;155:199e204.
[55] van der Graaf A, Avis HJ, Kusters DM, Vissers MN, Hutten BA, Defesche JC, et al.
Molecular basis of autosomal dominant hypercholesterolemia: assessment
in a large cohort of hypercholesterolemic children. Circulation 2011;123:
1167e73.
[56] Guardamagna O, Abello F, Anfossi G, Pirro M. Lipoprotein(a) and family his-
tory of cardiovascular disease in children with familial dyslipidemias. J Pediatr
2011;159:314e9.
[57] Pisciotta L, Fresa R, Bellocchio A, Pino E, Guido V, Cantafora A, et al. Cholesteryl
Ester Storage Disease (CESD) due to novel mutations in the LIPA gene. Mol
Genet Metab 2009;97:143e8.
[58] The Coronary Artery Disease (C4D) Genetics Consortium. A genome-wide
association study in Europeans and South Asians identifies five new loci for
coronary artery disease. Nat Genet 2011;43:339e44.
[59] The IBC 50K CAD Consortium. Large-scale gene-centric analysis identifies
novel variants for coronary artery disease. PLoS Genet 2011;7:e1002260.
[60] Wild PS, Zeller T, Schillert A, Szymczak S, Sinning CR, Deiseroth A, et al.
A genome-wide association study identifies LIPA as a susceptibility gene for
coronary artery disease. Circ Cardiovasc Genet 2011;4:403e12.
[61] Wolman M, Sterk VV, Gatt S, Frenkel M. Primary familial xanthomatosis with
involvement and calcification of the adrenals. Report of two more cases in
siblings of a previously described infant. Pediatrics 1961;28:742e57.
[62] Freudenberg F, Bufler P, Ensenauer R, Lohse P, Koletzko S. Cholesteryl ester
storage disease: an easily missed diagnosis in oligosymptomatic children.
Z Gastroenterol 2013;51:1184e7.
[63] Miltiadous G, Cariolou MA, Elisaf M. HDL cholesterol levels in patients with
molecularly defined familial hypercholesterolemia. Ann Clin Lab Sci 2002;32:
50e4.
[64] Iverson SA, Cairns SR, Ward CP, Fensom AH. Asymptomatic cholesteryl ester
storage disease in an adult controlled with simvastatin. Ann Clin Biochem
1997;34:433e6.[65] Guardamagna O, Cagliero P, Abello F. Management of inherited atherogenic
dyslipidemias in children. Ther Apher Dial 2013;17:150e61.
[66] Hamilton J, Jones I, Srivastava R, Galloway P. A new method for the mea-
surement of lysosomal acid lipase in dried blood spots using the inhibitor
Lalistat 2. Clin Chim Acta 2012;413:1207e10.
[67] Mukherjee M. Human digestive and metabolic lipases  a brief review. J Mol
Catal B Enzym 2003;22:369e76.
[68] Rosenbaum AI, Cosner CC, Mariani CJ, Maxfield FR, Wiest O, Helquist P.
Thiadiazole carbamates: potent inhibitors of lysosomal acid lipase and po-
tential NiemannPick type C disease therapeutics. J Med Chem 2010;53:
5281e9.
[69] Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K. The diagnosis
and management of non-alcoholic fatty liver disease: practice guideline by
the American Association for the Study of Liver Diseases, American College of
Gastroenterology, and the American Gastroenterological Association. Hep-
atology 2012;55:2005e23.
[70] Vajro P, Lenta S, Socha P, Dhawan A, McKiernan P, Baumann U, et al.
D56iagnosis of nonalcoholic fatty liver disease in children and adolescents:
position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastro-
enterol Nutr 2012;54:700e13.
[71] Thelwall PE, Smith FE, Leavitt MC, Canty D, Hu W, Hollingsworth KG, et al.
Hepatic cholesteryl ester accumulation in lysosomal acid lipase deficiency:
non-invasive identification and treatment monitoring by magnetic resonance.
J Hepatol 2013;59:543e9.
[72] Reiner Z. Statins in the primary prevention of cardiovascular disease. Nat Rev
Cardiol 2013;10:453e64.
[73] Tarantino MD, McNamara DJ, Granstrom P, Ellefson RD, Unger EC, Udall Jr JN.
Lovastatin therapy for cholesterol ester storage disease in two sisters. J Pediatr
1991;118:131e5.
[74] Tadiboyina VT, Liu DM, Miskie BA, Wang J, Hegele RA. Treatment of dyslipi-
demia with lovastatin and ezetimibe in an adolescent with cholesterol ester
storage disease. Lipids Health Dis 2005;4:26.
[75] Yokoyama S, McCoy E. Long-term treatment of a homozygous cholesteryl
ester storage disease with combined cholestyramine and lovastatin. J Inherit
Metab Dis 1992;15:291e2.
[76] McCoy E, Yokoyama S. Treatment of cholesteryl ester storage disease with
combined cholestyramine and lovastatin. Ann N Y Acad Sci 1991;623:453e4.
[77] Leone L, Ippoliti PF, Antonicelli R. Use of simvastatin plus cholestyramine in
the treatment of lysosomal acid lipase deficiency. J Pediatr 1991;119:1008e9.
[78] Abello F, Guardamagna O, Baracco V, Bonardi R. The treatment of colesteryl
storage disease (CESD) by ezetimibe monotherapy. Atheroscler Suppl
2010;11:28.
[79] Xu M, Liu K, Swaroop M, Porter FD, Sidhu R, Firnkes S, et al. d-Tocopherol
reduces lipid accumulation in NiemannPick type C1 and Wolman choles-
terol storage disorders. J Biol Chem 2012;287:39349e60.
[80] Tolar J, Petryk A, Khan K, Bjoraker KJ, Jessurun J, Dolan M, et al. Long-term
metabolic, endocrine, and neuropsychological outcome of hematopoietic cell
transplantation for Wolman disease. Bone Marrow Transplant 2009;43:21e7.
[81] Gramatges MM, Dvorak CC, Regula DP, Enns GM, Weinberg K, Agarwal R.
Pathological evidence of Wolman’s disease following hematopoietic stem cell
transplantation despite correction of lysosomal acid lipase activity. Bone
Marrow Transplant 2009;44:449e50.
[82] Yanir A, Allatif MA, Weintraub M, Stepensky P. Unfavorable outcome of he-
matopoietic stem cell transplantation in two siblings with Wolman disease
due to graft failure and hepatic complications. Mol Genet Metab 2013;109:
224e6.
[83] Ambler GK, Hoare M, Brais R, Shaw A, Butler A, Flynn P, et al. Orthotopic liver
transplantation in an adult with cholesterol ester storage disease. JIMD Rep
2013;8:41e6.
[84] Ferry GD, Whisennand HH, Finegold MJ, Alpert E, Glombicki A. Liver trans-
plantation for cholesteryl ester storage disease. J Pediatr Gastroenterol Nutr
1991;12:376e8.
[85] Grabowski GA. Therapy for lysosomal acid lipase deficiency: replacing a
missing link. Hepatology 2013;58:850e2.
[86] Balwani M, Breen C, Enns GM, Deegan PB, Honzik T, Jones S, et al. Clinical
effect and safety profile of recombinant human lysosomal acid lipase in pa-
tients with cholesteryl ester storage disease. Hepatology 2013;58:950e7.
[87] Whitley CB. North American Society for Pediatric Gastroenterology, Hep-
atology and Nutrition (NASPGHAN) Annual Meeting 2013 [Oral Presentation,
11 October 2013].
[88] Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. Eu-
ropean guidelines on cardiovascular disease prevention in clinical practice:
executive summary. Atherosclerosis 2007;194:1e45.
[89] Sloan HR, Fredrickson DS. Rare familial diseases with neutral lipid storage. In:
Stanbury JB, Wyngaarden JB, Fredrickson DS, editors. The metabolic basis of
inherited disease. New York: McGraw Hill Inc; 1972. p. 808.
[90] Yatsu FM, Hagemenas FC, Manaugh LC, Galambos T. Cholesteryl ester
hydrolase activity in human symptomatic atherosclerosis. Lipids 1980;15:
1019e22.
